SGS Increases Biopharma Characterization Capabilities
An expansion of laboratory facilities in Geneva, Switzerland expands SGS services for high-order structure analysis.
SGS announced on Aug. 28, 2018 that the company is expanding its biopharmaceutical testing capabilities in Geneva, Switzerland with the addition of a 200-sq.-m laboratory for early and late phase of biopharmaceutical characterization.
Scheduled to open by the end of the third quarter of 2018, the new laboratory will provide services for high-order structure analysis of biologics, including circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), extrinsic and intrinsic fluorescence, analytical ultracentrifugation (SV-AUC), size exclusion chromatography with multi-angle light scattering (SEC-MALS), dynamic light scattering (DLS) and differential scanning calorimetry (DSC).
When complete, the new laboratory will enable the Geneva facility-which opened in 1991 and is cGMP certified, GLP compliant, and FDA inspected-to offer ICH Q6B physico-chemical characterization of biological products, the company reported in a press announcement.
Source: SGS
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
